Login to Your Account

Longevity’s Hybridtides not just ‘me-too’ peptides

By Marie Powers
Staff Writer

Thursday, February 20, 2014
Based on its name, Longevity Biotech Inc. might be mistaken for a company seeking a prescription for aging. In a way, that’s true, admitted Scott Shandler, president and CEO, since the company is building a platform designed to help patients to live longer and healthier lives. But the name also is a bit of a double entendre, alluding to the company’s technical ability to improve the half-life of molecules of interest.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription